Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIFC1 | Q9BW19 | 1/20 | 0.64 |
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.53 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.53 |
| ▸ | GPR34 | Q9UPC5 | 5/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4831384 | 1.00 | KIFC1 (0.64) | KIFC1LRRK2GPR132GPR34ABCG2 | |
| SCHEMBL5926994 | 0.99 | KIFC1 (0.62) | KIFC1LRRK2GPR132GPR34ABCG2 | |
| SCHEMBL5926917 | 0.98 | KIFC1 (0.61) | KIFC1LRRK2GPR132GPR34ABCG2 | |
| SCHEMBL4829673 | 0.96 | KIFC1 (0.60) | KIFC1LRRK2GPR132GPR34ABCG2 | |
| SCHEMBL4829669 | 0.96 | KIFC1 (0.60) | KIFC1LRRK2GPR132GPR34ABCG2 | |
| SCHEMBL5927401 | 0.96 | KIFC1 (0.60) | KIFC1LRRK2GPR132GPR34 | |
| SCHEMBL5926945 | 0.91 | KIFC1 (0.60) | KIFC1LRRK2GPR132GPR34ABCG2 | |
| SCHEMBL4827796 | 0.91 | ABCG2 (0.62) | KIFC1LRRK2ABCG2 | |
| SCHEMBL4827793 | 0.91 | ABCG2 (0.62) | KIFC1LRRK2ABCG2 | |
| SCHEMBL5927554 | 0.90 | KIFC1 (0.56) | KIFC1LRRK2GPR132GPR34 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459472-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | disclosed |
| WO-2005014534-A1 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | CYP2F1, CYP3A43, PNPO | KIFC1 2072/4885LRRK2 1424/4885GPR132 3219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.